In-Silico Design Of A Potential Inhibitor Of Sars-Cov-2 S Protein

The SARS-CoV-2 virus has caused a pandemic and is public health emergency of international concern. As of now, no registered therapies are available for treatment of coronavirus infection. The viral infection depends on the attachment of spike (S) glycoprotein to human cell receptor angiotensin-converting enzyme 2 (ACE2). We have designed a protein inhibitor (Delta ABP-D25Y) targeting S protein using computational approach. The inhibitor consists of two alpha helical peptides homologues to protease domain (PD) of ACE2. Docking studies and molecular dynamic simulation revealed that the inhibitor binds exclusively at the ACE2 binding site of S protein. The computed binding affinity of the inhibitor is higher than the ACE2 and thus will likely out compete ACE2 for binding to S protein. Hence, the proposed inhibitor Delta ABP-D25Y could be a potential blocker of S protein and receptor binding domain (RBD) attachment.